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Dear Editor, 
Sclerostin (a product of SOST gene) acts as a main negative regulator of bone metabolism, exerting its 
properties through inhibition of canonical-WNT signaling-pathway (cWNT) in osteoblasts [1]. It is 
produced by osteocytes and bone marrow (BM) cells. cWNT activation is implicated in pathogenesis 
of Philadelphia chromosome negative myeloproliferative neoplasms (Ph- MPNs) [2,3], diseases 
characterized by remodelling of BM stroma and development of BM fibrosis/osteosclerosis during 
course of the disease. We aimed to investigate Sclerostin/SOST expression in BM tissues of patients 
with primary (PMF) and secondary post Ph- MPN myelofibrosis (SMF) and to assess its clinical 
correlations.  
We retrospectively investigated Sclerostin/SOST expression in BM of 66 diseased patients (51 PMF, 
15 post-PV/post-ET-SMF, diagnoses were established according to the WHO [4] and the IWG-MRT 
[5] criteria) and 18 age- and sex-matched controls (limited-stage aggressive Non-Hodgkin-lymphoma 
patients without BM involvement) using immunohistochemistry (IHC; Sclerostin 21933-1-AP rabbit 
polyclonal Proteintech primary antibody) and real-time polymerase-chain-reaction (RT-PCR; SOST 
Hs00228830_m1 Thermo Fischer Scientific TaqMan assay; evaluated from BM aspirates). Sclerostin 
expression was expressed as a percentage of positive cells. SOST mRNA expression was normalized 
to Abl and expressed as a ΔCT value. Correlations with clinical parameters were made. Optimal cut-
off values for survival were determined using the ROC-curve-analysis. The Mann-Whitney-U-test, the 
Spearman-rank-correlation, the Cox-Mantel-log-rank-test [6] and the Cox-regression-analysis were 
used. Analyses were done using MedCalc-Statistical-Software ver.18 (MedCalc Software bvba, 
Ostend, Belgium). P values <0.05 were considered statistically significant. All procedures were in 
accordance with the ethical standards of the responsible committee on human experimentation 
(institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. All patients 
provided written informed consent. 
Median age of patients was 67 years, 59% were males, 67% had grade II-III BM fibrosis, 70%, 11% 
and 2% were JAK2, CALR and MPL mutated, respectively. Median follow up of our cohort was 74 
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months with median overall survival of 69 months. Sclerostin/SOST expression did not significantly 
differ between PMF and SMF, nor between patients and controls. However, non-significantly higher 
expression was observed in myelofibrosis patients (both PMF and SMF) than in controls, result was 
near statistical significance for SOST (P=0.056). In diseased patients, higher Sclerostin expression 
measured by IHC was significantly correlated with lower percentage of circulatory blasts (Rho -0.28, 
P=0.042) and transfusion dependency (P=0.049). Higher SOST expression measured by RT-PCR was 
similarly significantly correlated with lower percentage of circulatory blasts (Rho -0.44, P=0.042), but 
also higher platelets (Rho 0.4, P=0.031) and smaller spleen size (Rho -0.6, P=0.001). We found no 
significant association of Sclerostin/SOST expression with JAK2, CALR and MPL mutation status or 
degree of bone marrow fibrosis. Patients with higher Sclerostin expression (HR=0.35, P=0.006) and 
higher SOST expression (HR=0.44, P=0.044) had superior overall survival than patients presenting 
with lower Sclerostin/SOST expression as shown in a Figure. This association remained significant for 
SOST (HR=0.21, P=0.025) after adjusting for age, gender and circulatory blasts (HR=1.06, P=0.002).  
Several interesting observations emerge from our study. First, Sclerostin expression might affect 
stem-cell-mobilization. SOST deficient mice were shown to have reduced expression of CXCL12 [7] 
which is important for this process, and reverse situation with higher Sclerostin/SOST expression 
might be possible. Additionally, patients with higher Sclerostin/SOST expression experienced 
improved survival, effect which might be prognostically independent of reduction in circulatory blasts 
(known prognostic parameter in myelofibrosis [8]) and which is probably mediated through cWNT 
inhibition. Due to the limited number of patients, our study was probably underpowered to detect 
statistical significance of some existing clinical correlations. Nevertheless, our findings emphasize the 
role of bone metabolism regulating cytokines, such as Sclerostin, in pathogenesis of Ph- MPNs and 
suggest that cWNT inhibition might be an interesting therapeutic approach in myelofibrosis patients. 
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Figure: A) Myelofibrosis patients presenting with higher Sclerostin (measured by 
immunohistochemistry) and B) SOST expression (measured by real-time polymerase chain reaction) 
experienced improved survival. The log-rank test was used. 
 
